Impact of ACA Subsidy Expiration on Surgical Demand and Intuitive Surgical's Future

Intuitive Surgical faced a significant decline in shares, dropping nearly 13% to their lowest point in over two years. This downturn followed a warning from the company about potential decreases in surgery demand linked to modifications in Affordable Care Act (ACA) plans. Despite this warning, Intuitive maintained its annual growth forecasts for surgical procedures.

Concerns arose regarding the volume of procedures amid the expiration of enhanced ACA subsidies, a risk downplayed earlier by Abbott. HCA Healthcare, the largest for-profit hospital operator in the United States, recently highlighted a decrease in surgical demand alongside an increase in uninsured patients following the expiration of pandemic-era ACA subsidies.

Evercore ISI analyst Vijay Kumar noted the unexpected weakness in Intuitive's U.S. procedures, stirring discussions about market conditions. Additional market responses saw Stryker's shares declining over 3%, while Boston Scientific and Medtronic experienced smaller decreases. Conversely, Abbott's shares rose by 2%.

Despite a potential $14 billion drop in market value for Intuitive, Leerink Partners analyst Mike Kratky described the selloff as "increasingly overblown," attributing some of the uncertainty to changes in insurance coverage affecting procedure growth in the U.S.

Future Outlook and Market Dynamics

Looking forward, Intuitive anticipates that its global da Vinci-assisted procedure growth in 2026 will fall within a forecast range of 13.5% to 15.5%. The da Vinci systems support a variety of surgeries, including weight loss procedures. In the recent quarter, procedure growth slowed to 12% from 14% in the first quarter, partly due to the postponement of non-urgent surgeries.

CEO David Rosa commented on the situation, suggesting that alterations in patient coverage and premium dynamics could influence when patients choose to seek treatment. The expiration of ACA subsidies had a modest adverse effect on procedure growth in the second quarter, though precise impacts were not disclosed. Following these developments, at least a dozen brokerages have reduced their price targets for Intuitive's stock.